Adjuvant chemotherapy after resection of adenocarcinoma of the periampullary region and the head of the pancreas
Adjuvant chemotherapy after resection of adenocarcinoma of the periampullary region and the head of the pancreas
复制标题
壶腹周围及胰头腺癌切除后的辅助化疗
DOI：
10.1007/bf00397924
复制
发表时间：
2004
影响因子：
3.6
通讯作者：
J. Jeekel
中科院分区：
文献类型：
--
作者：
T. Splinter;H. Obertop;T. Kok;J. Jeekel
从1980年至1984年，16名患者参加了一项非随机的初步研究，以探讨胰腺癌或壶腹周围癌根治性切除术后5个疗程的5-氟尿嘧啶、阿霉素和丝裂霉素C辅助治疗的可行性。这组患者的生存率与1977年至1984年期间单独接受根治性切除术的36例患者进行了比较。4例患者的辅助化疗剂量低于计算剂量的20%，4例患者的辅助化疗剂量为50%-60%，7例患者的辅助化疗剂量超过计算剂量的80%。化疗的耐受性很差。只有1例患者在化疗期间恢复了部分正常活动。根治性切除术后3年的精确生存率与未切除FAM的相似，分别为24%和28%。这些数据表明，维普莱手术或全胰腺切除术后辅助FAM是不可行的，因为附加术后和化疗诱导的发病率。
From 1980 till 1984 16 patients were entered into a non-randomized pilot study, to investigate the feasibility of five courses of adjuvant 5-fluorouracil, Adriamycin and mitomycin C 9FAM) after a curative resection of pancreatic or periampullary cancer. The survival of this group of patients was compared with that of 36 patients who underwent a curative resection alone between 1977 and 1984. Four patients received less than 20%, 4 patients 50%–60% and 7 patients≧80% of the calcuated dose of adjuvant chemotherapy. The chemotherapy was badly tolerated. Only 1 patient resumed some of his normal activity during chemotherapy. The 3-year actuarial survival after curative resection with and without FAM was similar, i.e. 24% and 28% respectively. These data suggest that adjuvant FAM after a Whipple's operation or total pancreatectomy is not feasible because of additive postoperative and chemotherapy-induced morbidity.